Early diagnostics Chip Diagnostics’ exosome-based biomarker platform targets early disease detection and therapy management, presenting a sales opportunity to biopharma and diagnostics customers seeking faster, cost-efficient screening workflows.

High-throughput potential The proprietary workflow scans trillions of exosomes individually, enabling scalable analysis that can appeal to large research groups and contract research organizations looking to improve throughput and data richness.

AI powered insights Integration of data and AI informatics suggests opportunities to upsell advanced analytics services, proprietary pipelines, and customized biomarker signature development for organ-specific disease profiling.

Resource-light offering Compared with traditional platforms, the emphasis on inexpensive, faster workflows creates a value proposition for cost-conscious labs, startup biotechs, and emerging markets seeking affordable diagnostic capabilities.

Growth through partnerships With a small team and revenue under one million, strategic alliances with larger CROs, diagnostic developers, and established instrument vendors could accelerate market access and co-development deals.